This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuhn, M. A. Articles by Furst, J. Search for Related Content PubMed PubMed Citation Articles by Kuhn, M. A. Articles by Furst, J.

(Circulation. 1996;93:1459-1463.)
© 1996 American Heart Association, Inc.

Articles

Biological Response to Bard Clamshell Septal Occluders in the Canine Heart

Micheal A. Kuhn, MD; Larry A. Latson, MD; John P. Cheatham, MD; Bruce McManus, MD, PhD; James M. Anderson, MD, PhD; Karen L. Kilzer, RT; Joseph Furst, MS

From the Department of Pediatric Cardiology, Cleveland (Ohio) Clinic Foundation (M.A.K., L.A.L., J.F.); the Section of Pediatric Cardiology, University of Nebraska Medical Center and Children's Memorial Hospital, Omaha (J.P.C., B.M., K.L.K.); and the Institute of Pathology, Case Western Reserve University, Cleveland, Ohio (J.M.A.).

Background The Clamshell Septal Occluder has been used to close various congenital heart defects. The purpose of this study was to evaluate the long-term biological response to this device after placement in the canine heart. Previous in vivo studies with device placement were limited to 60 days.

Methods and Results An atrial septal defect was created in dogs by blade septostomy followed by balloon dilation. Both old and new (redesigned) devices were placed. Angiographic follow-up was performed at 1, 3, and 6 months and 1 and 2 years after device placement with groups of dogs euthanitized at the same intervals. Gross and microscopic assessment was done on the explanted devices. The implants were covered at least 50% by neointima at 1 month and covered completely by 3 months. There was no thrombus formation. Areas of focal hemorrhage were evident at 1 month and were not present at 3 months. The fibrous capsule that covered the device became more densely organized and neovascularized by 2 years. A focal foreign body reaction at the device-tissue interface persisted for 2 years. There were no arm fractures with either the old or new devices in these dogs.

Conclusions The Bard Clamshell Septal Occluder is well tolerated in the canine heart for at least 2 years and elicits a normal healing process.

Key Words: catheterization • defects • pathology • heart defects, congenital • atrium

This article has been cited by other articles:

				J. Ritzema, I. C. Melton, A. M. Richards, I. G. Crozier, C. Frampton, R. N. Doughty, J. Whiting, S. Kar, N. Eigler, H. Krum, et al. Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients: Initial Experience With a New Permanent Implantable Device Circulation, December 18, 2007; 116(25): 2952 - 2959. [Abstract] [Full Text] [PDF]

				M. Sigler and C. Jux Biocompatibility of septal defect closure devices Heart, April 1, 2007; 93(4): 444 - 449. [Abstract] [Full Text] [PDF]

				C. Jux, H. Bertram, P. Wohlsein, M. Bruegmann, and T. Paul Interventional Atrial Septal Defect Closure Using a Totally Bioresorbable Occluder Matrix: Development and Preclinical Evaluation of the BioSTAR Device J. Am. Coll. Cardiol., July 4, 2006; 48(1): 161 - 169. [Abstract] [Full Text] [PDF]

				M. Pawelec-Wojtalik, J. Nozynski, M. Wojtalik, M. Piaszczynski, R. Surmacz, D. Bukowska, and W. Mrowczynski Is device closure for direct access valved stent implantation safe? Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 4 - 9. [Abstract] [Full Text] [PDF]

				H. W. Schuchlenz, S. Mannweiler, and D. Martin Marked foreign body reaction and thrombus formation after transcatheter closure of a patent foramen ovale J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 591 - 592. [Full Text] [PDF]

				C. Jux, H. Bertram, P. Wohlsein, M. Brugmann, P. Wuboldt, C. Fink, T. Paul, and G. Hausdorf Experimental ASD closure using autologous cell-seeded interventional closure devices Cardiovasc Res, January 1, 2002; 53(1): 181 - 191. [Abstract] [Full Text] [PDF]

				E. M. Zahn, N. Wilson, W. Cutright, and L. A. Latson Development and Testing of the Helex Septal Occluder, a New Expanded Polytetrafluoroethylene Atrial Septal Defect Occlusion System Circulation, August 7, 2001; 104(6): 711 - 716. [Abstract] [Full Text] [PDF]

				C A C Pedra, J Pihkala, K-J Lee, C Boutin, D G Nykanen, P R McLaughlin, D A Harrison, R M Freedom, and L Benson Transcatheter closure of atrial septal defects using the Cardio-Seal implant Heart, September 1, 2000; 84(3): 320 - 326. [Abstract] [Full Text] [PDF]

				A B. Thomsen, M Schneider, U Baandrup, E V Stenbøg, J M Hasenkam, J P Bagger, and G Hausdorf Animal experimental implantation of an atrial septal defect occluder system Heart, December 1, 1998; 80(6): 606 - 611. [Abstract] [Full Text]

				J. W. Moore Should Fontan FenestrationsBe Closed With Coils? Circulation, August 1, 1996; 94(3): 247 - 248. [Full Text]